Melanotan I (Afamelanotide): The Slower, Cleaner Cousin

Melanotan I, also known as MT-1 or afamelanotide, is a linear analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike its better-known relative MT-II, it has actually completed regulatory review: the implant form Scenesse is approved in the EU and US for erythropoietic protoporphyria, a rare photosensitivity disorder. That clinical pedigree makes MT-1 the more studied of the two melanocortin analogs, even though MT-II tends to get more attention online.

What it does

MT-1 binds melanocortin receptors, particularly MC1R, which drives eumelanin production in skin. The result is increased pigmentation that develops over weeks. Because MT-1 is more selective than MT-II, the typical side effect cluster is milder: less nausea, less flushing, less sexual side effect, and slower pigment onset. The trade-off is exactly that: slower and less dramatic.

Typical protocol shape

For the approved indication, MT-1 is delivered as a slow-release implant administered by a clinician. Self-experimenters who use injectable forms typically structure protocols as:

• A loading phase of small daily doses
• A maintenance phase with reduced frequency
• Sun or controlled UV exposure to actually trigger melanin synthesis
• Long pauses between cycles

Doses should not be copied from internet sources; the pharmacokinetics of compounded product are not standardized.

What to track daily

• Injection site reaction (redness, itch, lump)
• Nausea, if any, in the two hours post-injection
• Appetite shifts
• Mood and energy on a simple 1 to 5 scale
• Any new moles, freckles, or pigment changes

What to track weekly

• Standardized photos in consistent lighting at the same body sites
• A note on cumulative UV exposure
• Blood pressure, ideally at the same time of day
• Any spots that change in size, color, or border

Bloodwork worth doing

• Baseline comprehensive metabolic panel
• Liver function tests
• A dermatology check before starting, especially if you have a personal or family history of skin cancer

Realistic expectations

MT-1 pigment development is gradual. Expect weeks, not days, and expect that without UV exposure the effect is muted. People comparing MT-1 to MT-II usually describe it as "fewer side effects, slower results." That is a fair summary.

Common mistakes

• Expecting MT-II-speed results
• Skipping the dermatologist visit
• Using compounded product with no quality verification
• Ignoring new or changing skin lesions
• Treating tanning as the goal rather than the effect of UV plus melanocyte stimulation

A tracking template

In Peptide IA, log each injection with site and dose, and add a weekly photo entry tagged by body region. Photos are the only honest way to track pigment change; memory is unreliable here.

Safety notes

The long-term safety profile of melanocortin analogs in cosmetic use is not established. MT-1 in particular has not been studied for non-medical pigmentation use in well-controlled trials. Treat any new or changing mole as a reason to stop and see a dermatologist.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.